WEREWOLF THERAPEUTICS INC (HOWL) Fundamental Analysis & Valuation

NASDAQ:HOWL • US95075A1079

Current stock price

0.9047 USD
-0.07 (-6.7%)
At close:
0.906 USD
+0 (+0.14%)
After Hours:

This HOWL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. HOWL Profitability Analysis

1.1 Basic Checks

  • HOWL had negative earnings in the past year.
  • HOWL had a negative operating cash flow in the past year.
  • HOWL had negative earnings in each of the past 5 years.
  • HOWL had a negative operating cash flow in each of the past 5 years.
HOWL Yearly Net Income VS EBIT VS OCF VS FCFHOWL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M

1.2 Ratios

  • The Return On Assets of HOWL (-87.64%) is worse than 72.67% of its industry peers.
  • The Return On Equity of HOWL (-245.20%) is worse than 72.67% of its industry peers.
Industry RankSector Rank
ROA -87.64%
ROE -245.2%
ROIC N/A
ROA(3y)-54.86%
ROA(5y)-62.16%
ROE(3y)-124.94%
ROE(5y)-110.2%
ROIC(3y)N/A
ROIC(5y)N/A
HOWL Yearly ROA, ROE, ROICHOWL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for HOWL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HOWL Yearly Profit, Operating, Gross MarginsHOWL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. HOWL Health Analysis

2.1 Basic Checks

  • HOWL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for HOWL has been increased compared to 1 year ago.
  • Compared to 5 years ago, HOWL has more shares outstanding
  • The debt/assets ratio for HOWL is higher compared to a year ago.
HOWL Yearly Shares OutstandingHOWL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
HOWL Yearly Total Debt VS Total AssetsHOWL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -11.45, we must say that HOWL is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -11.45, HOWL is not doing good in the industry: 76.55% of the companies in the same industry are doing better.
  • There is no outstanding debt for HOWL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.45
ROIC/WACCN/A
WACC10.7%
HOWL Yearly LT Debt VS Equity VS FCFHOWL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M

2.3 Liquidity

  • HOWL has a Current Ratio of 1.62. This is a normal value and indicates that HOWL is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.62, HOWL is not doing good in the industry: 81.59% of the companies in the same industry are doing better.
  • HOWL has a Quick Ratio of 1.62. This is a normal value and indicates that HOWL is financially healthy and should not expect problems in meeting its short term obligations.
  • HOWL has a Quick ratio of 1.62. This is amonst the worse of the industry: HOWL underperforms 80.04% of its industry peers.
Industry RankSector Rank
Current Ratio 1.62
Quick Ratio 1.62
HOWL Yearly Current Assets VS Current LiabilitesHOWL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. HOWL Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 18.40% over the past year.
  • The Revenue for HOWL has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)18.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.04%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • HOWL is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.66% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y11.8%
EPS Next 2Y-10.6%
EPS Next 3Y-4.08%
EPS Next 5Y0.66%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HOWL Yearly Revenue VS EstimatesHOWL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2028 2029 2030 2031 2032 2033 50M 100M 150M 200M 250M
HOWL Yearly EPS VS EstimatesHOWL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -20 -40 -60 -80

More info and screens

Find the best growth stocksShow best growing peers

0

4. HOWL Valuation Analysis

4.1 Price/Earnings Ratio

  • HOWL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year HOWL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HOWL Price Earnings VS Forward Price EarningsHOWL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HOWL Per share dataHOWL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

  • A cheap valuation may be justified as HOWL's earnings are expected to decrease with -4.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.6%
EPS Next 3Y-4.08%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. HOWL Dividend Analysis

5.1 Amount

  • No dividends for HOWL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HOWL Fundamentals: All Metrics, Ratios and Statistics

WEREWOLF THERAPEUTICS INC

NASDAQ:HOWL (4/21/2026, 8:00:02 PM)

After market: 0.906 +0 (+0.14%)

0.9047

-0.07 (-6.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27
Earnings (Next)05-07
Inst Owners41.17%
Inst Owner Change-0.06%
Ins Owners1.4%
Ins Owner Change0%
Market Cap43.97M
Revenue(TTM)N/A
Net Income(TTM)-60.82M
Analysts85.45
Price Target6.38 (605.21%)
Short Float %3.02%
Short Ratio3.34
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.6%
Min EPS beat(2)9.5%
Max EPS beat(2)51.69%
EPS beat(4)4
Avg EPS beat(4)19.82%
Min EPS beat(4)0.47%
Max EPS beat(4)51.69%
EPS beat(8)5
Avg EPS beat(8)8.4%
EPS beat(12)9
Avg EPS beat(12)19.69%
EPS beat(16)12
Avg EPS beat(16)18.15%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)20.19%
PT rev (3m)20.19%
EPS NQ rev (1m)19.85%
EPS NQ rev (3m)19.85%
EPS NY rev (1m)21.81%
EPS NY rev (3m)28.84%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.77
P/tB 1.77
EV/EBITDA N/A
EPS(TTM)-1.33
EYN/A
EPS(NY)-1.17
Fwd EYN/A
FCF(TTM)-1.24
FCFYN/A
OCF(TTM)-1.24
OCFYN/A
SpS0
BVpS0.51
TBVpS0.51
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -87.64%
ROE -245.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.86%
ROA(5y)-62.16%
ROE(3y)-124.94%
ROE(5y)-110.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.62
Quick Ratio 1.62
Altman-Z -11.45
F-Score2
WACC10.7%
ROIC/WACCN/A
Cap/Depr(3y)19.2%
Cap/Depr(5y)122.61%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.04%
EPS Next Y11.8%
EPS Next 2Y-10.6%
EPS Next 3Y-4.08%
EPS Next 5Y0.66%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.5%
EBIT Next 3Y-12.19%
EBIT Next 5Y9.46%
FCF growth 1Y-6.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-7.3%
OCF growth 3YN/A
OCF growth 5YN/A

WEREWOLF THERAPEUTICS INC / HOWL Fundamental Analysis FAQ

What is the ChartMill fundamental rating of WEREWOLF THERAPEUTICS INC (HOWL) stock?

ChartMill assigns a fundamental rating of 1 / 10 to HOWL.


What is the valuation status of WEREWOLF THERAPEUTICS INC (HOWL) stock?

ChartMill assigns a valuation rating of 0 / 10 to WEREWOLF THERAPEUTICS INC (HOWL). This can be considered as Overvalued.


What is the profitability of HOWL stock?

WEREWOLF THERAPEUTICS INC (HOWL) has a profitability rating of 0 / 10.


What is the expected EPS growth for WEREWOLF THERAPEUTICS INC (HOWL) stock?

The Earnings per Share (EPS) of WEREWOLF THERAPEUTICS INC (HOWL) is expected to grow by 11.8% in the next year.